Skip to main content
TipRanks
Go Ultimate75% OFF

Biotricity (BTCY) AI Stock Analysis

124 Followers
BTCY

Biotricity

(Other OTC:BTCY)

Select Model
Rating:44Neutral
Price Target:$0.06â–¼(-3.33% Downside)
Action:reiterated
Date:11/11/26

The score is primarily held back by a high-risk financial structure (negative equity, sizable debt, and still-negative net income) despite operational improvement (strong revenue growth, very high gross margins, and positive operating profit). Technicals add caution due to a broader downtrend and negative MACD, while valuation is also pressured by negative earnings and no dividend support.

Positive Factors
Strong Revenue Growth and Gross MarginsStrong top-line momentum indicates expanding demand for Biotricity’s cardiac monitoring solutions, while consistently high gross margins provide room to support software, sales, and clinical adoption investments. Together, these trends can strengthen operating leverage as the business scales.
Negative Factors
Negative Equity and High LeveragePersistently negative equity and meaningful debt indicate a structurally strained balance sheet, limiting financial flexibility and increasing refinancing pressure. The pack also identifies dilution risk, so future funding needs could impose costs on existing shareholders while constraining strategic investment.

Biotricity (BTCY) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%BTCY-87.76%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.19M
Dividend Yield
―
Average Volume (3M)
50.53K
Price to Earnings (P/E)
-0.5
Beta (1Y)
0.17
Revenue Growth
13.40%
EPS Growth
43.26%
Country
US
Employees
46
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Biotricity Business Overview & Revenue Model

Company Description

Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States. The company's efforts are dedicated to supplying remote monitoring capa...

Biotricity Earnings Call Summary

Earnings Call Date:Feb 11, 2026(Q3-2026)|% Change Since:-75.00%|Next Earnings Date:Aug 15, 2022
Earnings Call SentimentPositive

The call conveyed clear operational momentum: double-digit revenue growth, meaningful gross margin expansion (+516 bps), consecutive positive EBITDA quarters (3) and six consecutive quarters of positive free cash flow, plus strong digital user and provider network expansion. Remaining challenges include a continued net loss ($1.1M), modest absolute revenue scale ($4.0M quarterly), concentration of revenue in technology fees (91.2%), and dependence on future FDA/regulatory clearances and large-account sales cycles. Overall, the positives (margin improvement, recurring revenue, cash-flow and EBITDA momentum, product traction and distribution reach) outweigh the remaining execution and scale risks.

Positive Updates

Revenue Growth
Total revenue for the quarter was $4.0M, up 10.2% year-over-year from $3.6M in the prior-year quarter.

Negative Updates

Net Loss Remains
Net loss attributable to common stockholders was $1.1M for the quarter (loss per share $0.042), improved from $1.3M (loss per share $0.054) year-over-year but still reflecting overall quarterly net losses.

Company Guidance

In the Q3 FY2026 call (period ended Dec. 31, 2025) management guided to continued top-line growth and a shift to profitability in calendar 2026—expecting to turn net‑income positive this year—citing Q3 revenue of $4.0M (up 10.2% vs. $3.6M), technology fees at 91.2% of revenue, gross profit $3.3M (+17.6% YoY) and gross margin 81.5% (up 516 bps from 76.4%), operating expenses $2.8M (down 4.2% YoY) with SG&A down 8.2% (~$195K) and R&D up $72K, EBITDA of $280K ($0.01/share) marking three consecutive quarters of positive EBITDA and six consecutive quarters of positive free cash flow, a net loss of $1.1M (vs. $1.3M) and loss per share $0.042 (vs. $0.054); they also highlighted user growth from 4,500 to >44,000 in two years, >2,500 providers supporting ~400,000 patients annually, expanded Biocore Pro pilots, GPO access to >90% of U.S. hospitals, and stated additional margin and expense improvements are expected with upcoming FDA clearances and international approvals.

Biotricity Financial Statement Overview

Summary

Operations are improving (sharp TTM revenue growth, very high gross margins, and a swing to positive operating profit), but the financial profile is still constrained by persistent net losses, negative stockholders’ equity, sizable leverage, and historically volatile cash flow.

Income Statement

54Neutral

Balance Sheet

18Very Negative

Cash Flow

33Negative
Financial statement breakdown
BreakdownTTMMar 2026Jun 2025Mar 2024Jun 2023Jun 2022
Income Statement
Total Revenue16.40M16.00M13.79M12.06M9.64M7.65M
Gross Profit13.36M12.95M10.56M8.36M5.44M4.57M
EBITDA1.86M2.44M-3.21M-6.73M-16.07M-18.56M
Net Income-2.69M-2.40M-8.42M-14.09M-18.66M-29.13M
Balance Sheet
Total Assets6.02M6.45M5.64M5.94M6.51M16.68M
Cash, Cash Equivalents and Short-Term Investments466.50K149.79K365.14K786.06K570.46K12.07M
Total Debt26.93M27.06M26.09M23.88M19.55M15.35M
Total Liabilities39.72M39.41M35.66M35.92M26.36M18.82M
Stockholders Equity-33.69M-32.96M-30.01M-29.98M-19.85M-2.14M
Cash Flow
Free Cash Flow161.66K-718.96K-2.38M-6.69M-13.55M-15.19M
Operating Cash Flow161.66K-718.96K-2.38M-6.69M-13.55M-15.16M
Investing Cash Flow00000-29.77K
Financing Cash Flow-68.90K557.74K1.93M6.74M2.00M25.17M

Biotricity Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.06

Price Trends

50DMA0.07Negative
100DMA0.09Negative
200DMA0.15Negative

Market Momentum

MACD-0.00Negative
RSI50.73Neutral
STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTCY, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.15, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 50.73 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BTCY.

Biotricity Risk Analysis

Biotricity disclosed 50 risk factors in its most recent earnings report. Biotricity reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.We are vulnerable to changes in political and economic conditions, including the effects of tariffs and/or international trade wars and disruptions to remittances.Q1, 2025
2.New or increased tariffs or other trade restrictions could have a material adverse effect on our business, financial condition, results of operations and cash flows.Q1, 2025

Biotricity Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BTCY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BTCYBTCY44Neutral$1.31M-0.468.23%―13.40%43.26%
HSCSHSCS40Underperform$10.56M-0.66-816.25%―-27.70%61.44%
VVOSVVOS40Underperform$3.29M-0.052616.82%―45.21%-10.29%
ADGMADGM37Underperform$1.77M-0.04-661.85%―-100.00%70.33%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%BTCYVVOSADGMHSCSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BTCY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BTCYBiotricity 0.06-0.46-88.46%
VVOSVivos Therapeutics, Inc.0.10-2.29-95.90%
ADGMAdagio Medical Holdings, Inc1.93-21.17-91.65%
HSCSHeart Test Laboratories, Inc.2.13-0.88-29.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026